TG Therapeutics, Inc. (TGTX)
| Market Cap | 4.32B |
| Revenue (ttm) | 531.90M |
| Net Income (ttm) | 447.47M |
| Shares Out | 146.20M |
| EPS (ttm) | 2.78 |
| PE Ratio | 10.64 |
| Forward PE | 19.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,728,082 |
| Open | 31.16 |
| Previous Close | 27.87 |
| Day's Range | 28.45 - 33.24 |
| 52-Week Range | 25.28 - 46.48 |
| Beta | 1.86 |
| Analysts | Strong Buy |
| Price Target | 54.75 (+85.34%) |
| Earnings Date | Mar 2, 2026 |
About TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glyco... [Read more]
Financial Performance
In 2024, TG Therapeutics's revenue was $329.00 million, an increase of 40.80% compared to the previous year's $233.66 million. Earnings were $23.38 million, an increase of 84.52%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for TGTX stock is "Strong Buy." The 12-month stock price target is $54.75, which is an increase of 85.34% from the latest price.
News
TG Therapeutics, Inc. (TGTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
TG Therapeutics, Inc. (TGTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
TG Therapeutics Stock Climbs After The Bell: Here's Why
TG Therapeutics, Inc. (NASDAQ: TGTX) shares climbed in Tuesday's extended trading after the company released its preliminary fourth quarter revenue estimates and provided an optimistic outlook for 202...
TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will present at the 44th An...
TG Therapeutics: What Wall Street Isn't Telling You
TG Therapeutics, Inc. is my favorite in the multiple sclerosis therapeutics market. In my opinion, it's Briumvi that has the best efficacy among anti-CD20 monoclonal antibodies, including Ocrevus and ...
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the 8th ...
TG Therapeutics: Concerns About Slowing Growth And New Competition
TG Therapeutics continues strong execution with Briumvi, maintaining beat-and-raise performance and robust financials, including a new $100 million buyback program. However, high investor expectations...
TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing
TGTX has seen rapid enrolment of the ENHANCE study which could allow a simplified dosing regime of IV Briumvi. A readout is possible for mid-2026. Investors may need to wait longer for the subcutaneou...
TG Therapeutics Q3 Earnings: Strong Quarter For Briumvi As CD20 Market Grows
TG Therapeutics, Inc. reported strong Q3 results, with Briumvi revenues up 84% year-over-year and full-year guidance raised to $585 million. TGTX continues to expand Briumvi's market presence, driven ...
TG Therapeutics, Inc. (TGTX) Q3 2025 Earnings Call Transcript
TG Therapeutics, Inc. ( TGTX) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, CEO & P...
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for th...
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a conso...
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with...
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), ...
TG Therapeutics, Inc. (TGTX) Presents at Cantor Global Healthcare Conference 2025 Transcript
TG Therapeutics, Inc. (NASDAQ:TGTX) Cantor Global Healthcare Conference 2025 September 3, 2025 10:20 AM EDT Company Participants Michael Weiss - Chairman, CEO & President Conference Call Participants...
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S.
TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that it has completed its previously authorized $100 million share repurchase program, which was initi...
TG Therapeutics to Participate in the Cantor Global Healthcare Conference
Fireside chat scheduled for Wednesday, September 3, 2025, at 10:20am ET Fireside chat scheduled for Wednesday, September 3, 2025, at 10:20am ET
TG Therapeutics, Inc. (TGTX) Q2 2025 Earnings Call Transcript
TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Adam Waldman - Chief Commercialization Officer Jenna Bosco - Senior Vice President ...
TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million Raises full year 2025 BRIUMVI U.S. net revenue target to approximately $570 - $575 million Con...
TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 4, 2025, at 8:30 AM ET to discuss results for the ...
TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel
TG Therapeutics, Inc.'s BRIUMVI saw Q1 2025 revenue surge 137% YoY to $119.7M, driven by strong U.S. growth. A subcutaneous version of TGTX's BRIUMVI is in phase 1 trials, with late-stage development ...
Evercore ISI's Julian Emanuel says now is the time to buy small-caps
Evercore ISI Senior Managing Director Julian Emanuel joins 'Closing Bell Overtime' to explain why he says now is the time to invest in small-caps.
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Gold...
TG Therapeutics: Estimates Could Soon Be Raised Again
TG Therapeutics remains on track, with Q1 revenue matching my model and potential for 110% growth in 2025 if price increases hold. Analyst estimates for 2025 revenue have risen sharply, and Q2 expecta...